Hartalega FY25 net profit surges nearly six-fold to RM75mil
Revenue rose 40.76 per cent to RM2.59 billion, compared with RM1.84 billion a year earlier.
"The significant increase of RM747 million or 41 per cent in revenue was mainly driven by a 40 per cent increase in sales volume," it said in a statement.
For the fourth quarter (Q4) ended March 31, 2025, Hartalega recorded a net profit of RM14.48 million, slightly lower than the RM14.9 million posted a year earlier.
Revenue for the quarter rose 15.3 per cent year-on-year to RM611.55 million, from RM530.34 million in the same quarter last year.
Higher sales volume and stronger selling prices lifted revenue, but net profit was dragged down by increased non-operating expenses during the quarter.
Hartalega chief executive officer Kuan Mun Leong said the group's full-year performance reflects encouraging signs of recovery for the sector.
Nevertheless, he cautioned that the operating environment remains volatile, with the global rubber glove market still facing oversupply and ongoing pricing pressure.
"In addition, US demand is expected to remain moderated in the near term following the earlier front-loading activities as well as the ongoing trade uncertainties.
"However, despite the impact of escalating US-China trade tensions on the global trade landscape, this could also serve as a catalyst for Malaysian manufacturers to regain export market share in the US," he said.
On the sector outlook, Kuan said the rubber glove industry's prospects remain positive.
He said global demand has surpassed pre-pandemic levels and is expected to grow further, driven by rising healthcare needs, greater hygiene awareness and broader usage across medical and non-medical sectors.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Focus Malaysia
5 days ago
- Focus Malaysia
Glove sector plunges down to 59% amid weak demand, tariff fears
Glove makers under Hong Leong Investment Bank (HLIB)'s coverage have declined significantly in the first half of 2025 (1H2025), with share prices down between -47% to -59%. The sector was first weighed down by growing investor risk aversion towards export-oriented sectors in early-2025 in view of the potential unfavourable reciprocal tariffs to be imposed on Malaysia imports by US President Trump post his inauguration. Sentiment was further dampened by earnings disappointments from Hartalega and Kossan in Feb 2025, which missed both our and consensus estimates. This was accompanied by a weak forward guidance from Hartalega, which flagged the possibility of returning to losses in upcoming quarters and raised concerns over Chinese peers' expansion into Southeast Asia (SEA). 'Based on our checks, sales orders for generic medical examination rubber gloves remain subdued since Feb 2025, with the US replenishment cycle guidance continuing to be pushed back,' said HLIB. According to the glove makers, the softness was primarily attributed to US distributors still sitting on the front-loaded inventories, while ex-US markets are facing fierce competition from Chinese players. We believe that the muted US demand faced by Malaysian manufacturers may also be linked to transhipment activities by Chinese peers, who rerouted shipments through Thailand, Indonesia, and Vietnam, before exporting to the US. This is evidenced by the rising market share and imported customs values from these countries, even as total US customs values for imported medical and surgical rubber gloves during March-April 2025 remained comparable to the front-loading period in October-November 2024. For pricing, glove makers have indicated the average selling point (ASP) for generic medical examination rubber gloves will remain in a downtrend due to lower raw material prices and ongoing fierce competition domestically and regionally. Based on our channel checks, there will be about 5-8 bil pcs/annum coming online in Vietnam and c.5bn pcs/annum in Indonesia by end-2025. In addition, we estimated that Intco will add 10 bil pcs/annum from China itself in 2025. On a positive note, there remains potential for a gradual demand shift among US buyers from vinyl gloves to nitrile rubber gloves should the ongoing 90-day tariff negotiations between the US and China end unfavourably. This substitution effect, estimated at an additional 28-38 bil pcs/annum, could help absorb the incoming supply from Intco's expanded capacity, thereby supporting the path toward restoring supply-demand equilibrium by 2026, based on our view. —July 21, 2025 Main image: Reuters
New Straits Times
5 days ago
- New Straits Times
Kossan stands out as HLIB's sole 'Buy' in glove sector
KUALA LUMPUR: Hong Leong Investment Bank Bhd (HLIB) has maintained its "Neutral" stance on the glove sector for the second half of 2025 (2H25), with Kossan Rubber Industries Bhd as its sole "Buy"-rated stock. The firm set a target price of RM2.30 for Kossan, and issued a "Hold" rating on Hartalega Holdings Bhd at RM1.48, and a "Sell" call on Top Glove Corp Bhd with a target price of 60 sen. "Kossan distinguishes itself through its differentiated strategies and robust financial footing, against a challenging industry backdrop," HLIB said in a research note today. HLIB said concerns over a supply-demand imbalance in the glove sector remain elevated, driven mainly by the aggressive expansion of Chinese, Vietnamese and Indonesian peers. "Chinese Intco Medical's cost advantages, driven by automation and favourable input economics, continue to underpin its relatively aggressive pricing strategy. "Transhipment flows from China via Thailand, Vietnam, and Indonesia are also displacing Malaysian exports and delaying volume recovery in the US market," it said. HLIB noted that share prices for glove makers fell between 47 per cent and 59 per cent in 1H25, weighed by earnings misses and weak investor sentiment. "Hartalega and Kossan missed both quarterly and consensus expectations in February, while Top Glove also reported below-par results in March. "Investor confidence was further undermined by another round of earnings misses from Hartalega, coupled with a more bearish industry outlook guidance. "We believe that the muted US demand faced by Malaysian manufacturers may also be linked to transhipment activities by Chinese peers," the firm said. Meanwhile, HLIB expects average selling prices (ASPs) to stay subdued due to raw material prices and intense regional competition, as ASPs peaked in December 2024. On global supply, HLIB projects an additional five to eight billion pieces per annum in capacity from Vietnam and 0.5 billion from Indonesia by the end of 2025. "We estimated that Intco will add approximately 10 billion pieces per annum of glove production capacity from its operations in China alone in 2025," it added.
New Straits Times
09-07-2025
- New Straits Times
Petronas Chemicals' earnings to stay weak as O&D spreads hit multi-year lows
KUALA LUMPUR: Petronas Chemicals Group Bhd's earnings are expected to remain under pressure in the coming quarters due to prolonged weakness in olefins and derivatives (O&D) spreads. In a research note, Maybank Investment Bank (Maybank IB) said the O&D subsector is still bearish due to the ongoing regional oversupply, mainly from China. It said O&D spreads continued to weaken in the second quarter of 2025, currently at multi-year lows since the Covid-19 pandemic in the first half of 2020. "This is given the ongoing regional supply glut, driven by fierce upcoming regional petrochemical complexes, mainly from China, due to the country's drive for self-sufficiency. "We are closely monitoring industry developments to identify any possible turnaround for the sector, as most naphtha-based petrochemical players are loss-making in the current environment," it said. Maybank IB said the weaker US dollar could result in unrealised foreign exchange (forex) losses, as the ringgit appreciated by five per cent against the greenback to 4.21 as at end-June 2025 from 4.43 at end-March 2025. Based on historical trends, the firm said Petronas Chemicals conducts a mark-to-market assessment and books in the forex impact on their assets on a quarterly basis. It said the company's upcoming second-quarter headline profits could be negatively affected by the revaluation of its shareholder loans to Pengerang Petrochemical Company (PPC), as well as the revaluation of the latter's payables. "Based on our estimates, Petronas Chemicals could register weaker core earnings in the second quarter due to a shutdown in PRefChem and declining O&D spreads," it said. Maybank IB, however, said a potential earnings upside could occur if the company's 50 per cent-owned PPC secures a "special discount" from PRefChem, contingent upon the latter's profitability following recent favourable gross refining margins. This subsidy could help offset PPC's losses and provide some relief to Petronas Chemicals' bottom line in the second half of 2025. Maybank IB kept its "Sell" call on the stock with an unchanged target price of RM2.59 a share.
